New Delhi, Sept 25 (UNI) Cadila Healthcare Ltd today said it has received the US Food and Drug Administration (FDA) approval for Hydroxychloroquine Sulfate tablets in the strength of 200 mg.
The drug falls in Disease Modifying Anti-Rheumatic Drug (DMARD) segment and is used in the management of rheumatoid arthritis.
The sales of Hydroxychloroquine Sulfate tablets in the US market in 2006 as per NDC Health was estimated at 30 million dollars.
The company will market the drug through its US subsidiary Zydus Pharmaceuticals (US) Inc, a statement said.
At present, the group has 27 approvals since the commencement of filing process in FY2003-04.